Article | August 1, 2023

Rare Disease Clinical Endpoints: Ingenuity Meets Practicality

GettyImages-1218518899-test-tube-research-lab-scientist-discovery

Endpoint science must intersect with endpoint practicality for a clinical trial to be successful. Assays must be developed to gauge whether, and to what extent, the therapy is accomplishing its target task, and if it is doing it with specificity. Typically, you are going to clinic without the benefit of volumes of animal research, or studies performed in healthy patients, neither of which are feasible/possible in gene therapy development. So, it often is hard to describe what is occurring, mechanistically, at any given time — or, more importantly, over a period of time — in humans.

Therapy developers not only need to prove clinical benefit, they need to prove the benefit is meaningful to the patient. An objective biological benefit is unlikely to be compelling for regulators and certainly will not convince payors; the results have to impact real life, or what is the point of treatment?

Creatively implementing as many elements or angles as possible in early study activities teaches researchers a lot about which endpoints do not matter or cannot be accomplished, be it remotely or in the clinic. Ultimately, the goal is to narrow that funnel significantly early in development, empowering researchers to move forward only with meaningful data, control the trial more closely, execute it more tightly, and lower its general late-stage burden.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader